ATXI (Avenue Therapeutics) Cyclically Adjusted FCF per Share: $-751.84 (As of Mar. 2026)


ATXI Avenue Therapeutics Inc ATXI
33 GF Score
Price $0.32
! 1 Warning Sign
View Full Analysis

What is Avenue Therapeutics Cyclically Adjusted FCF per Share?

Avenue Therapeutics ATXI 33 Cyclically Adjusted FCF per Share is $-751.84 as of Mar. 2026. GuruFocus rates ATXI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Avenue Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.133. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-751.84 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-12), Avenue Therapeutics's current stock price is $0.3188. Avenue Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-751.84. Avenue Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Avenue Therapeutics  (OTCPK:ATXI) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Avenue Therapeutics Cyclically Adjusted FCF per Share Related Terms


Avenue Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Avenue Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics Cyclically Adjusted FCF per Share Chart

Avenue Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -752.72

Avenue Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -773.77 -752.72 -751.84

ATXI vs AGTX, CLSDQ, BZYR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Avenue Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


ATXI
33GF Score
Avenue Therapeutics Inc ATXI
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Avenue Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.133/330.2130*330.2130
=-0.133

Current CPI (Mar. 2026) = 330.2130.

Avenue Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -29.875 241.018 -40.931
201609 -55.375 241.428 -75.739
201612 -9.125 241.432 -12.481
201703 -3.778 243.801 -5.117
201706 -207.000 244.955 -279.048
201709 -208.778 246.819 -279.319
201712 -474.222 246.524 -635.209
201803 -757.667 249.554 -1,002.555
201806 -669.222 251.989 -876.966
201809 -459.556 252.439 -601.141
201812 -137.556 251.233 -180.799
201903 -464.000 254.202 -602.744
201906 -932.067 256.143 -1,201.597
201909 -114.267 256.759 -146.957
201912 -333.067 256.974 -427.993
202003 -144.733 258.115 -185.161
202006 -87.800 257.797 -112.463
202009 -62.133 260.280 -78.827
202012 -79.533 260.474 -100.827
202103 -87.133 264.877 -108.626
202106 -46.933 271.696 -57.041
202109 -35.733 274.310 -43.015
202112 -75.188 278.802 -89.053
202203 -101.579 287.504 -116.669
202206 -49.632 296.311 -55.311
202209 -27.700 296.808 -30.818
202212 -65.141 296.797 -72.475
202303 -21.257 301.836 -23.255
202306 -45.291 305.109 -49.017
202309 -8.231 307.789 -8.831
202312 -6.815 306.746 -7.336
202403 -5.552 312.332 -5.870
202406 -2.015 314.175 -2.118
202409 -1.806 315.301 -1.891
202412 -0.403 315.605 -0.422
202503 -0.399 319.799 -0.412
202506 -0.055 322.561 -0.056
202509 0.120 324.800 0.122
202512 -0.268 324.054 -0.273
202603 -0.133 330.213 -0.133

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-751.84 mean?
Avenue Therapeutics (ATXI) has a Cyclically Adjusted FCF per Share of $-751.84 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Avenue Therapeutics and its competitors.
Is Avenue Therapeutics' Cyclically Adjusted FCF per Share too high?
Avenue Therapeutics' current Cyclically Adjusted FCF per Share is $-751.84. Overall, Avenue Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' Cyclically Adjusted FCF per Share compare to AGTX and CLSDQ?
Avenue Therapeutics' Cyclically Adjusted FCF per Share of $-751.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Avenue Therapeutics and its competitors. Avenue Therapeutics's current Cyclically Adjusted FCF per Share is $-751.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current Cyclically Adjusted FCF per Share of $-751.84. The current Cyclically Adjusted FCF per Share is $-751.84. Avenue Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current Cyclically Adjusted FCF per Share is $-751.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
33GF Score

Get the complete analysis for ATXI

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price